The latest Akebia Therapeutics Inc. (AKBA) Stock Technical Bulletin
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
Yummy or too sour? Akebia Therapeutics Inc. (AKBA) Stock
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
Is it possible to sustain this rally? Akebia Therapeutics Inc. (AKBA) Stock
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
The latest Akebia Therapeutics Inc. (AKBA) Stock Technical Bulletin
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
In the current cycle, Akebia Therapeutics Inc. (AKBA) Stock is showing signs of growth
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
How Akebia Therapeutics Inc. (AKBA) Stock converts water flow into cash flow
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
Akebia Therapeutics Inc. (AKBA) Stock to return to profitability in the near future
BTIG Research raised the price target for the Akebia Therapeutics Inc. (NASDAQ:AKBA) stock to “a Buy”. The rating was released on November 29, 2023, according to finviz. The research report from Piper Sandler has upgraded the stock from Neutral to Overweight, with a price target set at $4. The stock was downgraded by Piper Sandler, […]
